Overview
This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
Eligibility
6 months after metabolic surgery; 18 years ≤ age ≤ 55 years; Body Mass Index (BMI) ≥ 28 kg/m^2